RxDoctor Payments DataLook up a doctor →

Howard Brooks, MD

Dermatology · Washington, DCNPI 1568687739

Payments from drug & device makers

$8,798in general payments, 2019–2025

Across 479 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$1K
  • Novartis$944
  • Sanofi$786
  • Lilly USA, LLC$656
  • Dermavant Sciences, Inc.$547
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$8,47096%
  • Education$3284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,798 in reported general payments places this provider in the 60th percentile of 73 dermatology providers in District of Columbia.

See all dermatology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$472,763
Medicare patients
1,825
Services billed
7,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa27$546,962
Dupixent PenDupilumab59$232,595
RinvoqUpadacitinib13$85,273
Humira PenAdalimumab13$80,094
Dupixent SyringeDupilumab20$75,703
Clobetasol Propionate278$17,127
VtamaTapinarof11$15,306
Fluorouracil128$8,888
Pimecrolimus20$6,918
Ivermectin20$6,740
Desonide80$5,240
Tretinoin40$3,814
Metronidazole58$2,950
Doxycycline Hyclate142$2,759
Ketoconazole150$2,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,183$85,27313 claims
Dermavant Sciences, Inc.Vtama$547$15,30611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 73 dermatology providers in District of Columbia.

Other dermatology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →